In search of a cure for PCOS
The SPIOMET4Health project

30.09.22

MMM is participating in an EU project, SPIOMET4Health, which aims at providing a treatment for Polycystic Ovary Syndrome (PCOS), a leading cause of infertility, while raising awareness about the prevalence of this hormonal disorder among young women.

About Polycystic Ovary Syndrome (PCOS) and its prevalence

Polycystic Ovary Syndrome (PCOS) is the leading cause of fertility problems in women. Indeed, it is negatively affecting the health and quality of life of approximately 110 million women globally in many ways. That’s between 5 and 10% of all women worldwide, and even of their offspring. It is the most common hormonal disorder among women of reproductive age. Women with PCOS may have a range of symptoms such as infrequent or prolonged menstrual periods, and excessive levels of male hormones (androgens); these are usually present in women in small amounts and may result in excessive body hair (hirsutism) and acne and also contribute to abnormal body fat distribution. PCOS is also associated with lifelong disorders such as type 2 Diabetes, premature vascular ageing, premenopausal cancer and a higher risk of premature birth in pregnancy.

These are symptoms that not only affect physical health but can have knock on effects on women’s confidence and self-esteem. Studies show that approximately 40% of women with PCOS are known to experience depression or anxiety. This emotional impact is also reinforced by the potential sub-fertility that PCOS can cause. PCOS not only has repercussions on the patient, but it also incurs a cost on society: it is estimated that its annual cost is approximately €23 billion in the European health sector. Currently, there is no approved treatment for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young women

The EU project SPIOMET4HEALTH and MMM’s role

Therefore, the European Union’s Horizon 2020 research and innovation program is funding the SPIOMET4HEALTH project that aims to provide a new treatment for adolescent girls and young adult women with polycystic ovary syndrome.

MMM is participating in the European project as a communication partner, but also to alert politicians to the urgency of the situation. We hope that Europe can offer more funds to help young women suffering from this syndrome.

Our role is to spread the word about the importance of adolescent girls and young adult women aged 12 to 24, who suffer from PCOS, to come forward and participate in the project’s phase II clinical trial in different centers in Europe. The aim being to test whether this new therapeutic approach has the potential to improve the health-related quality of life for millions of women with PCOS.

Our goal?

Find a new treatment for SOPK: SPIOMET in a single tablet (SPI, 50 mg + PIO, 7.5 mg + MET, 850 mg) administered daily, together with specific lifestyle measures, aims to normalize ovulation and endocrine-metabolic status. SPIOMET4HEALTH will also impinge on the underlying mechanisms responsible for the development of PCOS and its results will serve as a basis for a Phase III clinical trial that will enable the exploitation of this novel approach throughout Europe.

This new treatment has the potential to become a preconception strategy that will likely be followed by spontaneous ovulation or conception, normal pregnancies, and a healthier next generation.

Learn more

Keywords:

Most read articles

MMM welcomes first ever Human Rights Council resolution on Care

11.10.23

UN Geneva, Human Rights Council - Entitled ‘Centrality of care and support from a human rights perspective’, this landmark resolution was presented by the governments of Argentina, Iceland, Mexico

Lire plus

A snapshot of our Women at the Peace Table Conference

20.06.23

It was by all accounts, a remarkable gathering of global peacemakers. They came from all over the world to lend their voice and support to the message of the Conference:

Lire plus

Call to action: make 2024 the EU year for Women’s Mental Health

09.10.23

In June this year, the European Union (EU) Commission announced a new high-priority initiative to address the mental health of all Europeans.

Lire plus
See all the articlesof the category

News from the MMM European Delegation

Mothers Can-Bringing mothers back to work

13.05.24

MMM is working on the project “Mothers Can-Bringing mothers back to work”, a European partnership between six countries (Belgium, Cyprus, Germany, Romania, Spain and Greece). The project aims to support mot

Read more

Breaking the intergenerational cycle of poverty by investing in children and their families

07.05.24

Make Mothers Matter participated in the conference “Investing in an inclusive and fair future for Europe. European Child Guarantee: from engagement to reality", organised within the framework of the Belgian p

Read more

La Hulpe Declaration: positive step for social justice in the EU

07.05.24

MMM welcomes the recent adoption of La Hulpe Declaration, under the Belgian presidency. This inter-institutional document aims at shaping the future social agenda of the European Union for the period 2024-2029.

Read more

Every mother should have access to the long-term care she needs and deserves

20.04.24

In a timely joint statement, we at Make mothers Matter, along with 16 European NGOs, have urged EU policymakers to prioritise long-term care in the upcoming 2024-2029 legislature. This call comes as the Belgian

Read more

Empowering Families for a Better Tomorrow Insights from We Learn Everywhere Conference

13.02.24

This event, marked by insightful presentations and discussions, addressed the challenges and opportunities that exist in parenting within our complex society and highlighted the tools created to provide parents

Read more

Parental tools for mental wellbeing: join us in Brussels to find out the results

09.01.24

The "We Learn Everywhere" (WLE) project is a pioneering initiative that has made significant strides in promoting family well-being through education and support for parents and children across Europe. As this

Read more